Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study - PubMed
5 hours ago
- #pharmacovigilance
- #musculoskeletal
- #diabetes
- Incretin-based therapies, including GLP-1 RAs, DPP-4is, and tirzepatide, are widely used for type 2 diabetes mellitus (T2DM).
- Musculoskeletal adverse events (AEs) associated with these therapies were analyzed using FAERS reports from Q1 2004 to Q2 2024.
- GLP-1 RAs were linked to back pain, myalgia, and neck mass, while tirzepatide was associated with muscle atrophy and neck mass.
- DPP-4is like sitagliptin, linagliptin, and alogliptin showed signals for osteoarthritis, rhabdomyolysis, and arthritis.
- Sex-, age-, and weight-related differences in AEs were noted for several drugs including dulaglutide, liraglutide, semaglutide, and saxagliptin.
- Median onset of AEs was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days).
- Weibull analysis indicated an early-failure pattern for most agents, except saxagliptin, which suggested a borderline wear-out trend.
- Vigilant monitoring is recommended during early GLP-1 RA or tirzepatide therapy and later during DPP-4i use to optimize patient safety.